Claims for Patent: 10,507,180

Summary for Patent: 10,507,180

Title:	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Abstract:	Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
Inventor(s):	Palmer; Pamela (San Francisco, CA), Schreck; Thomas (Portola Valley, CA), Tzannis; Stelios (Petaluma, CA), Hamel; Larry (Pacific Grove, CA), Poutiatine; Andrew I. (Mill Valley, CA)
Assignee:	AcelRx Pharmaceuticals, Inc. (Redwood City, CA)
Application Number:	16/153,301
Patent Claims:	1. A dosage form for oral transmucosal administration to a subject, comprising: an analgesic drug, wherein said dosage form is bioadhesive and has a volume of less than 30 microliters or a mass of less than 30 mg. 2. The dosage form of claim 1, wherein the drug is sufentanil or a congener of sufentanil. 3. The dosage form of claim 2, wherein the congener of sufentanil is alfentanil, lofentanil, carfentanil, remifentanil, trefentanil or mirfentanil. 4. The dosage form of claim 1, wherein the dosage form has a volume of less than 10 microliters or a mass of less than 10 mg. 5. The dosage form of claim 1, wherein after administration of the dosage form to the subject, at least 50% of the drug delivery of the active drug occurs via the oral transmucosal route. 6. The dosage form of claim 5, wherein after administration of the dosage form to the subject, at least 55% of the drug delivery of the active drug occurs via the oral transmucosal route. 7. The dosage form of claim 5, wherein after administration of the dosage form to the subject, at least 60% of the drug delivery of the active drug occurs via the oral transmucosal route. 8. The dosage form of claim 1, wherein the transmucosal administration is to the sublingual membrane. 9. The dosage form of claim 8, wherein the administration is to the buccal membrane. 10. The dosage form of claim 1, wherein a single oral transmucosal administration of the dosage form to the subject results in a bioavailability of greater than 65%. 11. The dosage form of claim 10, wherein a single oral transmucosal administration of the dosage form to the subject results in a bioavailability of greater than 75%. 12. The dosage form of claim 11, wherein a single oral transmucosal administration of the dosage form to the subject results in a bioavailability of greater than 80%. 13. A drug delivery device comprising the dosage form of claim 1. 14. A method of treating pain in a subject, comprising administering a dosage form to the oral mucosa of a subject, wherein said dosage form is bioadhesive and comprises an active drug, wherein said dosage form is bioadhesive and has a volume of less than 30 microliters or a mass of less than 30 mg. 15. The method of claim 14, wherein the drug is an analgesic drug. 16. The dosage form of claim 14, wherein the drug is sufentanil or a congener of sufentanil. 17. The dosage form of claim 16, wherein the congener of sufentanil is alfentanil, lofentanil, carfentanil, remifentanil, trefentanil or mirfentanil. 18. The method of claim 14, wherein the dosage form has a volume of less than 10 microliters or a mass of less than 10 mg. 19. The method of claim 14, wherein after administration of the dosage form to the subject, at least 50% of the drug delivery of the active drug occurs via the oral transmucosal route. 20. The method of claim 14, wherein after administration of the dosage form to the subject, at least 55% of the drug delivery of the active drug occurs via the oral transmucosal route. 21. The method of claim 20, wherein after administration of the dosage form to the subject, at least 60% of the drug delivery of the active drug occurs via the oral transmucosal route. 22. The method of claim 14, wherein the transmucosal administration is to the sublingual membrane. 23. The method of claim 22, wherein the administration is to the buccal membrane. 24. The method of claim 14, wherein a single oral transmucosal administration of the dosage form to the subject results in a bioavailability of greater than 65%.